Addressing the task of finding new ways to diagnose and treat cancer as well as other conditions through laboratory-derived oncological therapeutics, Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The development of QSOX1 as a unique cancer biomarker has led the firm's principals to important discoveries based on the testing hundreds of human samples. The firm's lead compound has been tested in animal studies and has shown to significantly to reduce tumors in 2-3 weeks
